Clinical Trial Update: A Phase 1 Study of PPI-668 in Healthy Volunteers and Patients With Hepatitis C Virus (HCV) Genotype 1 [Phase 1]

View source ↗

Summary

Phase 1 trial of PPI-668 in healthy volunteers and patients with chronic hepatitis C (genotype 1) has completed, evaluating safety and pharmacokinetics.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• PPI-668

Snippet

Sponsor: Presidio Pharmaceuticals, Inc. | Conditions: Hepatitis C, Chronic | Phase 1 | Status: COMPLETED